<DOC>
	<DOCNO>NCT02012985</DOCNO>
	<brief_summary>The purpose study determine Oxalobacter formigenes effective lower urinary oxalate level patient primary hyperoxaluria .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Oxabact ( OC5 ) Patients With Primary Hyperoxaluria</brief_title>
	<detailed_description />
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<criteria>Signed informed consent ( applicable age subject ) . Male female subject ≥ 2 year age ( Germany &amp; France ) / Male female subject ≥ 5 year age ( United Kingdom ) A diagnosis PH type I , II III ( determine standard diagnostic method ) . A mean urinary oxalate excretion &gt; 1.0 mmol/24h/1.73m2 , base least three eligible urine collection perform baseline ( week 14 ) . Renal function define estimate GFR ≥ 40 ml/min normalise 1.73m2 body surface area , creatinine clearance ≥ 40 ml/min normalise 1.73m2 body surface area . Subjects receive vitamin B6 must receive stable dose least 3 month prior screen must change dose study . Subjects receive vitamin B6 study entry must willing refrain initiate pyridoxine study participation . Inability collect complete 24hour urine sample . Each urine collection evaluate completeness base urine qualitative criterion . Inability swallow size 4 capsule twice daily 8 10 week . Subjects undergone transplantation ( solid organ bone marrow ) . The existence secondary hyperoxaluria , e.g . hyperoxaluria due bariatric surgery chronic gastrointestinal disease cystic fibrosis , chronic inflammatory bowel disease shortbowel syndrome . Use antibiotic O. formigenes sensitive , include chronic use , history two course antibiotic use past 6 month , current antibiotic use , antibiotic use within 14 day initiate study medication . Subjects require immune suppressive therapy . Current treatment ascorbic acid preparation . Pregnancy . Women childbearing potential use adequate contraceptive precaution oral , transdermal , injectable , implanted contraceptive , IUD , complete abstinence , use condom sexual partner , sterile sexual partner . Presence medical condition Principal Investigator consider likely make subject susceptible adverse effect study treatment unable follow study procedure . Participation study investigational product , biologic , device , agent within 30 day prior screen willing forego form investigational treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hyperoxaluria</keyword>
	<keyword>oxalate</keyword>
	<keyword>PH</keyword>
</DOC>